These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

49 related articles for article (PubMed ID: 2565583)

  • 1. Efficacy and tolerability of a new antipsychotic compound (savoxepine): results of a pilot-study.
    Möller HJ; Kissling W; Dietzfelbinger T; Stoll KD; Wendt G
    Pharmacopsychiatry; 1989 Jan; 22(1):38-41. PubMed ID: 2565583
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and tolerability of a new antipsychotic compound (risperidone): results of a pilot study.
    Möller HJ; Pelzer E; Kissling W; Riehl T; Wernicke T
    Pharmacopsychiatry; 1991 Nov; 24(6):185-9. PubMed ID: 1725925
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuroleptic profile of cipazoxapine (Savoxepine), a new tetracyclic dopamine antagonist: clinical validation of the hippocampus versus striatum ratio model of dopamine receptors in animals. A preliminary report.
    Butler B; Bech P
    Pharmacopsychiatry; 1987 May; 20(3):122-6. PubMed ID: 2885867
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Savoxepine: invalidation of an "atypical" neuroleptic response pattern predicted by animal models in an open clinical trial with schizophrenic patients.
    Wetzel H; Wiedemann K; Holsboer F; Benkert O
    Psychopharmacology (Berl); 1991; 103(2):280-3. PubMed ID: 1674161
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive value of pharmaco-electroencephalography in early human-pharmacological evaluations of psychoactive drugs. First example: savoxepine.
    Herrmann WM; Schärer E; Delini-Stula A
    Pharmacopsychiatry; 1991 Nov; 24(6):196-205. PubMed ID: 1687485
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Savoxepine versus haloperidol. Reasons for a failed controlled clinical trial in patients with an acute episode of schizophrenia.
    Volz HP; Möller HJ; Gerebtzoff A; Bischoff S
    Eur Arch Psychiatry Clin Neurosci; 2002 Apr; 252(2):76-80. PubMed ID: 12111340
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Results of an open phase II study with zotepine--a new neuroleptic compound.
    Fleischhacker WW; Unterweger B; Barnas C; Stuppäck C; Hinterhuber H
    Pharmacopsychiatry; 1987 Feb; 20(1 Spec No):64-6. PubMed ID: 2883686
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [New chemotherapy approaches to psychoses].
    Olié JP; Baylé FJ
    Encephale; 1997 Apr; 23 Spec No 2():2-9. PubMed ID: 9273302
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Zotepine in the treatment of negative symptoms in chronic schizophrenia.
    Fleischhacker WW; Barnas C; Stuppäck C; Unterweger B; Hinterhuber H
    Pharmacopsychiatry; 1987 Feb; 20(1 Spec No):58-60. PubMed ID: 2883684
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antipsychotic efficacy of the dopaminergic autoreceptor agonist EMD 49980 (Roxindol). Results of an open clinical study.
    Klimke A; Klieser E
    Pharmacopsychiatry; 1991 Jul; 24(4):107-12. PubMed ID: 1684439
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of the sigma receptor ligand EMD 57445 (panamesine) in patients with schizophrenia: an open clinical trial.
    Huber MT; Gotthardt U; Schreiber W; Krieg JC
    Pharmacopsychiatry; 1999 Mar; 32(2):68-72. PubMed ID: 10333165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interictal psychoses in comparison with schizophrenia--a prospective study.
    Tadokoro Y; Oshima T; Kanemoto K
    Epilepsia; 2007 Dec; 48(12):2345-51. PubMed ID: 17666070
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Initial use of risperidone in the treatment of acutely exacerbated schizophrenic patients--an interim analysis].
    Pajonk FG; Schreiner A; Peters S; Rettig K; Degner D; Rüther E
    Fortschr Neurol Psychiatr; 2003 May; 71(5):249-54. PubMed ID: 12740756
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-dose zotepine in the maintenance treatment of schizophrenia.
    Fleischhacker WW; Stuppäck C; Barnas C; Unterweger B; Hinterhuber H
    Pharmacopsychiatry; 1987 Feb; 20(1 Spec No):61-3. PubMed ID: 2883685
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amisulpride--an open clinical study of a new benzamide in schizophrenic patients.
    Mann K; Bartels M; Bauer H; Gaertner HJ
    Pharmacopsychiatry; 1984 Jul; 17(4):111-5. PubMed ID: 6147865
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cannabidiol monotherapy for treatment-resistant schizophrenia.
    Zuardi AW; Hallak JE; Dursun SM; Morais SL; Sanches RF; Musty RE; Crippa JA
    J Psychopharmacol; 2006 Sep; 20(5):683-6. PubMed ID: 16401651
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conventional versus novel antipsychotics: changing concepts and clinical implications.
    Remington G; Chong SA
    J Psychiatry Neurosci; 1999 Nov; 24(5):431-41. PubMed ID: 10586534
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Zotepine versus placebo in the treatment of schizophrenic patients with stable primary negative symptoms: a randomized double-blind multicenter trial.
    Möller HJ; Riedel M; Müller N; Fischer W; Kohnen R
    Pharmacopsychiatry; 2004 Nov; 37(6):270-8. PubMed ID: 15551193
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Long-term clinical experience with clozapine].
    Gelly F; Chambon O; Marie-Cardine M
    Encephale; 1997; 23(5):385-96. PubMed ID: 9453932
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological long-term treatment strategies in first episode schizophrenia--study design and preliminary results of an ongoing RCT within the German Research Network on Schizophrenia.
    Gaebel W; Möller HJ; Buchkremer G; Ohmann C; Riesbeck M; Wölwer W; Von Wilmsdorff M; Bottlender R; Klingberg S
    Eur Arch Psychiatry Clin Neurosci; 2004 Apr; 254(2):129-40. PubMed ID: 15146342
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.